Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
» ELN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ELN Guru Trades in

Q2 2013

ELN Guru Trades in Q2 2013

Eric Mindich 3,604,184 sh (New)
John Paulson 5,100,000 sh (New)
Mario Gabelli 55,800 sh (New)
Jeremy Grantham 300,000 sh (New)
Daniel Loeb 8,500,000 sh (New)
Steven Cohen 1,719,463 sh (+327.81%)
Jean-Marie Eveillard 2,739,100 sh (+17.87%)
Daniel Loeb 3,500,000 sh (unchged)
Vanguard Health Care Fund 19,470,300 sh (unchged)
Robert Bruce 165,900 sh (unchged)
Paul Singer 2,569,634 sh (unchged)
Jim Simons Sold Out
Seth Klarman Sold Out
Stanley Druckenmiller Sold Out
Michael Price 823,150 sh (-25.17%)
Andreas Halvorsen 4,661,400 sh (-50.26%)
» More
Q3 2013

ELN Guru Trades in Q3 2013

Jim Simons 1,261,597 sh (New)
Louis Moore Bacon 424,117 sh (New)
Jeremy Grantham 1,040,996 sh (+247.00%)
Mario Gabelli 149,600 sh (+168.10%)
Steven Cohen 3,159,074 sh (+83.72%)
Paul Singer 3,200,000 sh (+24.53%)
Daniel Loeb 10,000,000 sh (+17.65%)
Jean-Marie Eveillard 2,000 sh (unchged)
Robert Bruce 165,900 sh (unchged)
Vanguard Health Care Fund 19,470,300 sh (unchged)
John Paulson Sold Out
Michael Price Sold Out
Andreas Halvorsen Sold Out
Jean-Marie Eveillard 1,000,000 sh (-63.49%)
Eric Mindich 855,000 sh (-76.28%)
» More
Q4 2013

ELN Guru Trades in Q4 2013

Steven Cohen Sold Out
Jean-Marie Eveillard Sold Out
Louis Moore Bacon Sold Out
Robert Bruce Sold Out
Paul Singer Sold Out
Eric Mindich Sold Out
Vanguard Health Care Fund Sold Out
Jim Simons Sold Out
Daniel Loeb Sold Out
Mario Gabelli Sold Out
Jeremy Grantham Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ELN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:0M2W.UK, EAN.Germany, DRX.Germany,
Elan Corp PLC, an Irish public limited company, is a neuroscience-based biotechnology company. It was incorporated as a private limited company in Ireland in December 1969 and became a public limited company in January 1984. It is a neuroscience-based biotechnology company and its business is organized into two business units namely BioNeurology and Elan Drug Technologies (EDT). On September 16, 2011, it announced the completion of the merger between Alkermes, Inc. and EDT. In BioNeurology, the company is developing therapies for serious diseases that have long been considered intractable, including MS, Alzheimer's disease and Parkinson's disease. EDT develops and manufactures pharmaceutical products that deliver clinically meaningful benefits to patients, using its experience and proprietary drug technologies in collaboration with pharmaceutical companies. Tysabri, a treatment for relapsing forms of MS, competes mainly with Avonex, Betaseron(r), Berlex. The pharmaceutical industry is subject to significant regulation by international, national, state and local governmental regulatory agencies.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK